Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610
- Written by PR Newswire
 |
TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has recently completed the first batch of subject enrollment for its novel adjuvanted recombinant shingles vaccine, REC610.
The study is a randomized,...
